Ursodeoxycholic acid (UDCA) is a natural hydrophilic bile acid. Initially, it was extracted from bear bile, but with the development of technology, it is now mainly obtained through methods such as chemical synthesis and biosynthesis. Its unique chemical structure and biological activity endow it with important application value in the treatment of various hepatobiliary diseases.
Firstly, UDCA exhibits significant efficacy in the treatment of primary biliary cholangitis (PBC). PBC is a chronic liver disease characterized by the gradual destruction of bile ducts and intrahepatic cholestasis. UDCA reduces the side effects of hydrophobic bile acids on bile duct cells by increasing bile secretion and lowering the concentration of hydrophobic bile acids in bile. In addition, UDCA can improve patients' liver enzyme levels, delay disease progression, reduce recurrence rates, and prolong patients' survival. Therefore, it has been approved by the U.S. FDA as a first-line drug for the treatment of PBC.
Secondly, UDCA also shows good effects in the treatment of cholesterol gallstones. By reducing the saturation of cholesterol in bile, UDCA can promote the dissolution of cholesterol stones. Furthermore, it increases the content of bile salts in bile, thereby reducing the formation of gallstones. This makes UDCA one of the important drugs for the treatment of gallstones.
Beyond the aforementioned applications, UDCA also plays an important role in the treatment of other hepatobiliary diseases. For instance, it is used in the treatment of bile reflux gastritis, other cholangitides, and intrahepatic cholestasis of pregnancy. UDCA improves liver function by promoting the flow and secretion of bile, and reducing bile stasis in the liver. Moreover, it possesses immunomodulatory, anti-inflammatory, and anti-fibrotic effects, and has shown potential application value in the treatment of diseases such as non-alcoholic fatty liver disease.
In the pharmaceutical field, the value of UDCA is reflected not only in its wide clinical applications but also in the continuous optimization and innovation of its production process. The development of modern synthesis technologies has made the production of UDCA more efficient and environmentally friendly. For example, the biosynthesis method uses biological enzymes to catalyze the synthesis of UDCA, which has the advantages of environmental friendliness, simplicity, and high efficiency. These technological advancements not only improve the purity and quality of the product but also reduce production costs, providing strong support for the wide application of UDCA.
To summarize, UDCA has wide applications in the treatment of hepatobiliary diseases and significant value in the pharmaceutical industry. With further research on its pharmacological effects and continuous improvement of production technologies, the application prospects of UDCA will be broader, providing more effective drug options for the treatment of hepatobiliary diseases.












